Literature DB >> 32172543

miR-505-3p controls chemokine receptor up-regulation in macrophages: role in familial hypercholesterolemia.

Rafael Escate1, Pedro Mata2, Jose Maria Cepeda3, Teresa Padreó1, Lina Badimon1,4.   

Abstract

Familial hypercholesterolemia (FH) conveys a high risk of premature atherosclerosis as a result of lifelong exposure to high LDL cholesterol levels that are not fully reduced by standard-of-care lipid-lowering treatment. Inflammatory mediators have played a role in the progression of atherosclerotic lesions. Here, we investigated whether innate immunity cells in patients with FH have a specific proinflammatory phenotype that is distinct from that of cells in normal participants. To this end, miR-505-3p-a microRNA related to chronic inflammation-and its target genes were investigated in monocyte-derived macrophages (MACs) of patients with FH (FH-MACs) and non-FH controls (co-MACs). On the basis of the profiler PCR array analysis of agomiR-505-3p-transfected MACs, we identified the chemokine receptors, CCR3, CCR4, and CXCR1, as genes that are regulated by miR-505-3p via the transcription factor, RUNX1. miR-505-3p was significantly down-regulated, whereas CCR3, CCR4, CXCR, and RUNX1 were increased in FH-MAC compared with co-MAC, with the increase being more evident in the proinflammatory M1-like FH-MAC. Chemokine receptor levels were unrelated to LDL plasma levels at entry, but correlated with age in patients with FH, not in controls. In summary, we demonstrate for first time to our knowledge that MACs from FH-MACs have an inflammatory phenotype that is characterized by the up-regulation of CCR3, CCR4, and CXCR1 under the control of miR-505-3p. These results suggest a chronic inflammatory condition in FH innate immunity cells that is not reverted by standard lipid-lowering treatment.-Escate, R., Mata, P., Cepeda, J.M., Padró, T., Badimon, L. miR-505-3p controls chemokine receptor up-regulation in macrophages: role in familial hypercholesterolemia. FASEB J. 32, 601-612 (2018). www.fasebj.org. © FASEB.

Entities:  

Keywords:  LDL cholesterol; age; inflammatory markers; innate immunity; microRNAs

Year:  2018        PMID: 32172543     DOI: 10.1096/fj.201700476R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  5 in total

Review 1.  MicroRNAs as New Regulators of Neutrophil Extracellular Trap Formation.

Authors:  Sonia Águila; Ascensión M de Los Reyes-García; María P Fernández-Pérez; Laura Reguilón-Gallego; Laura Zapata-Martínez; Inmaculada Ruiz-Lorente; Vicente Vicente; Rocío González-Conejero; Constantino Martínez
Journal:  Int J Mol Sci       Date:  2021-02-20       Impact factor: 5.923

2.  Untargeted sequencing of circulating microRNAs in a healthy and diseased older population.

Authors:  Lukas Streese; Philippe Demougin; Paula Iborra; Alexander Kanitz; Arne Deiseroth; Julia M Kröpfl; Arno Schmidt-Trucksäss; Mihaela Zavolan; Henner Hanssen
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

3.  Expression of MicroRNAs Is Dysregulated by HIV While Mycobacterium tuberculosis Drives Alterations of Small Nucleolar RNAs in HIV Positive Adults With Active Tuberculosis.

Authors:  Oskar Olsson; Fregenet Tesfaye; Rolf Søkilde; Jolanta Mazurek; Markos Abebe; Habtamu Yeba; Abraham Aseffa; Sten Skogmar; Taye Tolera Balcha; Carlos Rovira; Per Björkman; Marianne Jansson
Journal:  Front Microbiol       Date:  2022-02-22       Impact factor: 5.640

4.  Circulating MicroRNA-505 May Serve as a Prognostic Biomarker for Hypertension-Associated Endothelial Dysfunction and Inflammation.

Authors:  Qinbo Yang; Peiwei Wang; Yiqing Cai; Yimeng Cui; Jingang Cui; Xiaoye Du; Yu Chen; Teng Zhang
Journal:  Front Cardiovasc Med       Date:  2022-04-29

5.  Alternative C3 Complement System: Lipids and Atherosclerosis.

Authors:  Maisa Garcia-Arguinzonis; Elisa Diaz-Riera; Esther Peña; Rafael Escate; Oriol Juan-Babot; Pedro Mata; Lina Badimon; Teresa Padro
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.